The in vitro activity of a prototype 2-aryl carbapenem, L-695,256, against gram-positive bacteria was examined. All streptococci and oxacillin-susceptible and -resistant staphylococci were inhibited at concentrations of Յ0.125, Յ0.125, and 4 g/ml, respectively. The activity of L-695,256 was superior to that of imipenem against other organisms intrinsically resistant to ␤-lactams.
The introduction of imipenem into clinical practice represented a major advance. Its broad antibacterial spectrum is potentially advantageous for empiric treatment of infections prior to identification of causative organisms and for treatment of polymicrobial infections. In addition, because of resistance to hydrolysis by most clinically important ␤-lactamases and other favorable characteristics, this carbapenem often retains activity against nosocomial isolates of gram-negative bacteria resistant to other ␤-lactam antibiotics (3, 4, 18) . Two notable exceptions to this favorable pattern of activity are methicillinresistant staphylococci and penicillin-resistant enterococci, both of which display reduced susceptibility to imipenem (20) . In both instances, resistance to ␤-lactams can be attributed to the presence of penicillin-binding proteins with reduced affinities for these agents (7, 8, 14, 16, 22) . Neither of the two more recently developed carbapenems, meropenem and biapenem, offers any activity advantage over imipenem against these organisms in particular or against gram-positive bacteria in general (13, 20) .
L-695,256 ( Fig. 1 ) is one of a series of novel 2-aryl carbapenems selected for evaluation because of its unusually good activity against methicillin-resistant staphylococci (19) . This drug binds to PBP 2a of Staphylococcus aureus and to PBP 5 of Enterococcus hirae with substantially greater affinity than comparable ␤-lactams (6, 9). The present study was undertaken to examine the in vitro activity of L-695,256 against a variety of gram-positive bacteria, including strains specifically collected because of their resistance to ␤-lactams or other antibiotics.
(This work was presented in part at the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, Fla., October 1994 [12] .)
Most of the organisms included in this study were clinical isolates obtained at Deaconess Hospital and Massachusetts General Hospital, Boston, Mass. Strains of streptococci demonstrating resistance to ␤-lactams and strains of vancomycinresistant enterococci had been referred to our collection from a variety of sources (13, 20) . L-695,256 and imipenem were provided by Merck, Sharp & Dohme Research Laboratories, Rahway, N.J. Other susceptibility reference powders were gifts from the indicated sources: oxacillin, Bristol-Myers Squibb Co., Syracuse, N.Y.; clindamycin, Upjohn Co., Kalamazoo, Mich.; erythromycin and vancomycin, Eli Lilly & Co., Indianapolis, Ind.; and teicoplanin, Marion Merrell Dow, Inc., Cincinnati, Ohio.
Antimicrobial susceptibility was determined by an agar dilution technique as previously described (13) . Mueller-Hinton II agar (Becton Dickinson Microbiology Systems, Cockeysville, Md.) was used and was supplemented with 5% sheep blood when streptococci, diphtheroids, lactobacilli, pediococci, and Leuconostoc spp. were tested. Bacterial suspensions in Mueller-Hinton broth were applied with a replicating device yielding inocula of approximately 10 4 CFU. Plates were read after 18 to 20 h of incubation except for plates containing diphtheroids, which were incubated for 48 h to allow adequate growth.
To examine the bactericidal activity of the new carbapenem against enterococci, three highly gentamicin-resistant strains of Enterococcus faecalis were studied by time-kill methods. Bacteria were suspended to a concentration of 10 6 CFU/ml in glucose phosphate broth containing L-695,256 at eight times the MIC (2 g/ml) or at 20 g/ml. Flasks were incubated 24 h at 35ЊC without agitation, and samples were removed at 0, 4, and 24 h for colony counts, which were determined in duplicate. No attempt to inactivate the antibiotic prior to colony count determination was made.
The in vitro activities of L-695,256 and comparable agents are shown in Table 1 . All isolates of oxacillin-susceptible staphylococci were inhibited by both imipenem and the new agent at low concentrations. In contrast, on the basis of either the MIC at which 50% of the isolates are inhibited or the MIC at which 90% of the isolates are inhibited, L-695,256 was 32-to 64-fold more active than imipenem against oxacillin-resistant staphylococci, inhibiting all strains at concentrations of Յ4 g/ml. All streptococci were susceptible to L-695,256 at Յ0.125 g/ml. L-695,256 was eightfold more active than imipenem against penicillin-resistant strains of pneumococci and viridans streptococci, among which were 11 isolates for which MICs of penicillin exceeded 1.0 g/ml. L-695,256 was 4-to 16-fold more active than imipenem or penicillin against enterococci. Ninety percent of the vancomycin-resistant E. faecalis isolates were inhibited by 0.5 g of the new compound per ml compared with 4 g of penicillin or imipenem per ml. Strains of Enterococcus faecium and Enterococcus raffinosus (and Corynebacterium jeikeium) were more resistant to all ␤-lactams tested, but against these, L-695,256 was again more active than penicillin or imipenem. L-695,256 was eightfold more active than imipenem against Leuconostoc spp. and Lactobacillus spp., but the two drugs had comparable activities against Listeria monocytogenes, Pediococcus spp. and two strains of Erysipelothrix.
The new carbapenem demonstrated bacteriostatic activity against three isolates of E. faecalis by the time-kill method. At either 2 or 20 g/ml, a reduction of Յ1 log 10 CFU/ml in viable organisms relative to the inoculum was observed at 4 h of incubation, and a rate of killing of Յ2 log 10 CFU/ml was noted by 24 h of incubation.
The new 2-aryl carbapenem, L-695,256, proved to be at least as active as imipenem against a broad range of gram-positive bacteria studied here. In particular, L-695,256 was substantially more active than imipenem against oxacillin-resistant staphylococci and highly penicillin-resistant enterococci. Concentrations of the new drug inhibiting 90% of isolates in this study were virtually identical to concentrations observed and reported in preliminary form by others, including those determined by agar dilution (17) and by broth microdilution with 2% NaCl supplementation (10) .
The unusual activity of L-695,256 in vitro against grampositive organisms that are intrinsically resistant to ␤-lactam antibiotics because of the presence of low-affinity penicillinbinding protein targets appears to be related to the enhanced binding affinity of this agent compared with that of imipenem for PBP 2a of staphylococci (6, 9) and PBP 5 of enterococci (9) . The potential relevance of these observations to in vivo infection is supported by studies showing the 2-aryl carbapenem to be more active than imipenem in animal models of infection caused by a homogeneously methicillin-resistant strain of S. aureus (6, 21) .
Methicillin resistance in S. aureus has been recognized as a significant clinical problem for more than two decades (2) . The importance of methicillin-resistant coagulase-negative staphylococci as nosocomial pathogens has been increasingly appreciated (1, 11) . In light of the increasing prevalence of vancomycin-resistant (and multiply drug-resistant) enterococci among hospital isolates since 1989 (5) and the demonstration of the transferability of vancomycin resistance from enterococci to S. aureus under experimental conditions (15) , there is serious concern that vancomycin resistance may emerge among clinical isolates of methicillin-resistant staphylococci, with devastating consequences.
On the basis of its in vitro activity against staphylococci, enterococci, and streptococci that have reduced susceptibility to ␤-lactams at the target level, L-695,256 appears to be an important prototype for the development of novel carbapenems with enhanced activity against these organisms.
